Can Zepbound Cause Depression?

TL;DR

• Depression was not identified as a significant side effect in Zepbound's clinical trials. In SURMOUNT studies, depression rates were nearly identical between tirzepatide group (~1.8%) and placebo group (~1.9%).

• In January 2026, FDA requested manufacturers remove suicide and depression warnings from GLP-1 receptor agonist labels after a comprehensive meta-analysis of over 107,000 patients found no increased risk.

• Post-marketing pharmacovigilance data from Europe showed that depression was most commonly reported psychiatric event across GLP-1 medications (including tirzepatide), but psychiatric reports made up only 1.2% of all adverse event reports.

What Did Clinical Trials Actually Show?

The SURMOUNT trials, which led to Zepbound's FDA approval for weight management, enrolled thousands of adults with obesity and tracked them for up to 72 weeks. Depression was not flagged as an adverse event occurring at meaningfully higher rates in tirzepatide-treated patients compared to those on placebo.

In fact, a pooled analysis of SURMOUNT-1, SURMOUNT-2, and SURMOUNT-3 data found that participants on tirzepatide actually showed improved scores on PHQ-9, a validated screening tool for depressive symptoms, compared to placebo at week 72. This makes sense given that obesity itself is strongly associated with depression, and significant weight loss often improves overall quality of life, self-image, and mood.

A separate FDA meta-analysis reviewed data from over 107,000 patients across multiple GLP-1 receptor agonist trials and found no increased risk of suicidal ideation or behavior compared to placebo. This analysis covered tirzepatide, semaglutide, liraglutide, and other drugs in class. Based on these findings, FDA in early 2026 moved to have manufacturers remove suicide related warnings from GLP-1 medication labels.

Why Does Label Mention Depression at All?

Before January 2026 update, Zepbound's prescribing information included a warning advising providers to monitor patients for emergence or worsening of depression, suicidal thoughts or behaviors, and any unusual changes in mood or behavior. This warning was not based on signals from Zepbound's own clinical trials. It was carried over from broader class of weight loss medications as a precautionary measure.

Several older weight loss drugs (some of which have since been removed from market) were associated with psychiatric side effects. Regulatory agencies applied similar warnings across newer drugs in category, including GLP-1 receptor agonists, as a safety net while post-marketing data accumulated.

The distinction matters. A label warning does not mean drug causes condition. It means FDA wanted providers to watch for it while real-world data was being collected. Now that data is in, warning is being removed.

What Does Post Marketing Data Say?

While clinical trials did not find a depression signal, post-marketing surveillance tells a more nuanced story. A pharmacovigilance analysis published in International Journal of Clinical Pharmacy examined adverse event reports submitted to European EudraVigilance database for semaglutide, liraglutide, and tirzepatide between 2021 and 2023.

Out of over 31,000 total adverse event reports, 372 involved psychiatric events, which is about 1.2% of all reports. Depression was most commonly reported psychiatric event at 50.3% of those psychiatric reports, followed by anxiety at 38.7% and suicidal ideation at 19.6%. Nine deaths were reported, all associated with liraglutide or semaglutide, not tirzepatide.

These numbers need context. Adverse event databases capture reports from patients and providers, but they do not establish causation. People with obesity already have higher baseline rates of depression and anxiety. Someone experiencing a depressive episode while taking Zepbound may report event even if medication is not cause. The 1.2% figure is consistent with background psychiatric rates in this patient population.

That said, data underscores that mood should be monitored in anyone on a GLP-1 medication, not because drug is proven to cause depression, but because population being treated is already at elevated risk.

How Can Zepbound Indirectly Affect Mood?

Even without a direct pharmacological link to depression, several aspects of Zepbound experience can influence how you feel emotionally.

Rapid weight loss changes your relationship with food. For many people, eating is deeply tied to comfort, stress relief, social connection, and routine. When appetite suppression removes food as an emotional outlet, adjustment can feel disorienting. This is not clinical depression, but it can feel a lot like it.

GI side effects like persistent nausea, vomiting, or diarrhea can drain your energy and disrupt sleep. Chronic nausea in particular can mimic symptoms of depression, including low motivation, fatigue, and social withdrawal. If GI symptoms are driving your mood down, addressing those symptoms directly may help more than anything else.

Nutritional deficiencies can develop when calorie intake drops significantly. Reduced intake of B vitamins, iron, magnesium, and omega-3 fatty acids can all contribute to low mood and fatigue. This is especially relevant during first months of treatment when appetite suppression is most intense.

If you are noticing persistent fatigue alongside mood changes, this article on whether tirzepatide makes you tired covers fatigue side of equation and what might help.

What Should You Watch For?

It is reasonable to stay aware of your mood while on Zepbound, especially during first 8 to 12 weeks when dose escalations and rapid weight loss are happening.

Signs that warrant a conversation with your provider include persistent sadness or emptiness lasting more than 2 weeks, loss of interest in activities you normally enjoy, difficulty sleeping or sleeping much more than usual, trouble concentrating or making decisions, increased irritability or emotional numbness, and withdrawal from friends, family, or social activities.

If you experience any thoughts of self-harm or suicide, seek help immediately. Contact 988 Suicide and Crisis Lifeline by calling or texting 988.

People with a pre existing history of depression, anxiety, bipolar disorder, or prior suicidal ideation should let their prescriber know before starting Zepbound. Closer monitoring during first months of treatment is recommended. For a broader look at psychiatric effects of tirzepatide, this guide on tirzepatide side effects and anxiety covers anxiety dimension as well.

Conclusion

The clinical evidence does not support a direct link between Zepbound and depression. Trial data shows similar depression rates between tirzepatide and placebo, and a massive FDA meta-analysis found no increased risk of psychiatric events. However, experience of rapid weight loss, reduced eating, GI symptoms, and nutritional shifts can all affect how you feel emotionally. Stay aware of your mood, communicate with your provider, and do not dismiss persistent changes as just part of process.